Pemigatinib is a targeted therapy drug that specifically inhibits fibroblast growth factor receptors (FGFRs). It is primarily used in the treatment of certain types of cancer that exhibit aberrant FGFR signaling. The drug is a tyrosine kinase inhibitor, which means it works by blocking the enzyme tyrosine kinase, a key player in cell signaling pathways involved in cancer cell growth and survival.
